Pengumuman
Kegiatan Ilmiah INNOVATE (Indonesia Oncology Scientific Update)
Penyedia Pembelajaran:Pusat Kanker Nasional Rumah Sakit Kanker Dharmais
SeminarMenengah
1+
4.9
117 Peserta Terdaftar
Classical
Gratis
Tentang Seminar
Target Peserta
Dokter Spesialis Patologi Anatomi (5 SKP)
Dokter Spesialis Penyakit Dalam (5 SKP)
Dokter (5 SKP)
Tujuan Seminar
Kompetensi
Tanggal Pelaksanaan
Sabtu, 06 Juli 2024 pukul 01:00 s/d Minggu, 07 Juli 2024 pukul 16:59
Konten Seminar
Konten yang akan diajarkan dalam Seminar ini antara lain:1.
A.1. Introduction: Molecular biology aspects of Breast Cancer HER2+
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 01.50
-
Sabtu, 6 Juli 2024 pukul 02.00
2.
A.2 Diagnosis of Breast Cancer HER2+ and HER2-low
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 02.00
-
Sabtu, 6 Juli 2024 pukul 02.50
3.
Study of T-Dxd in Breast Cancer HER2+: DB01, DB02, DB03 studies
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 02.45
-
Sabtu, 6 Juli 2024 pukul 03.05
4.
Study of T-Dxd in Breast Cancer HER2- low DB04, DB06 studies
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 03.05
-
Sabtu, 6 Juli 2024 pukul 03.25
5.
Critical appraisal of Study of T-Dxd in Breast Cancer HER2+: DB01, DB02, DB03 study plus Investigator- Initiated Studies (real-world evidence/independent studies) to determine a Level of Evidence of T-Dxd based on CEMB and Safety Profiles
Oleh:
Fasilitator
Classical
Fairmont Hotel
Sabtu, 6 Juli 2024 pukul 03.35
-
Sabtu, 6 Juli 2024 pukul 03.55
6.
Critical apraisal of Study of T-Dxd in Breast Cancer HER2-low DB04, DB06 study plus Investigator-Initiated Studies (real- world evidence/independent studies) to determine a Level of Evidenceece of T
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 03.55
-
Sabtu, 6 Juli 2024 pukul 04.15
7.
Interactive Case Discussion with Polling : Clinical experience of T-Dxd in Breast Cancer HER2-low
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 04.35
-
Sabtu, 6 Juli 2024 pukul 04.55
8.
Interactive Case Discussion with Poling : Clinical experience of T-Dxd in Breast Cancer HER2+
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 04.55
-
Sabtu, 6 Juli 2024 pukul 05.15
9.
Hepatobiliary Tumor Immune Microenvironment & Rationale to Target Immune Checkpoint Inhibitor
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 06.00
-
Sabtu, 6 Juli 2024 pukul 06.20
10.
Pivotal Study of Durvalumab in Biliary Trach Cancer BTC (TOPAZ-1 Study)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 06.20
-
Sabtu, 6 Juli 2024 pukul 06.40
11.
Pivotal Study of Tremelimumab + Durvalumab in HCC (HIMALAYA STUDY)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 06.40
-
Sabtu, 6 Juli 2024 pukul 07.00
12.
Critical appraisal of the Pivotal Study study on Durvalumab in Biliary Tract Cancer & Real- World Evidence (Efficacy; level of evidence)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 07.10
-
Sabtu, 6 Juli 2024 pukul 07.30
13.
Critical appraisal of the studies on Tremelimumab + Durvalumab in HCC & Real- World Evidence (Efficacy; level of evidence; safety; grade of recommendation)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 07.30
-
Sabtu, 6 Juli 2024 pukul 07.50
14.
Evolving Treatment Concept and New Data of Combination Therapy for mCRPC (PROpel Study)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 08.30
-
Sabtu, 6 Juli 2024 pukul 08.50
15.
Two is Better than One : Abiraterone-Prednison Combined with Olaparib are Better Than Use of Either Type of Agent Alone or in Sequence (BRCAAway Study)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 08.50
-
Sabtu, 6 Juli 2024 pukul 09.10
16.
Olaparib Combined with Abiraterone versus Olaparib Monotherapy or Patients with Metastatic Castration- resistant Prostate Cancer Progressing after Abiraterone (China RWE Study)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Sabtu, 6 Juli 2024 pukul 09.20
-
Sabtu, 6 Juli 2024 pukul 09.40
17.
6 Years ELEVATE TN: New Approach on Acalabrutinib Treatment to Manage Naive CLL Patient
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 01.30
-
Minggu, 7 Juli 2024 pukul 02.00
18.
ECHO Phase III trial: Acalabrutinib combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma.
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 02.00
-
Minggu, 7 Juli 2024 pukul 02.30
19.
The Role of Fish Testing and NGS in Analyzing Molecular Mutation of CLL and How to interpret the test result for prognosis high-risk patient
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 02.30
-
Minggu, 7 Juli 2024 pukul 03.00
20.
Clinical Experience MCL patient treated with Acalabrutinib in combination with BR
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 03.00
-
Minggu, 7 Juli 2024 pukul 03.15
21.
Clinical Experience of Adjuvant therapy in Early- stage EGFR- mutated NSCLC (ADAURA study & case)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 03.30
-
Minggu, 7 Juli 2024 pukul 04.00
22.
From Bench to Bedside:The Real-World Evidence of Treating Lung Cancer (RWE FLAURA & case)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 04.00
-
Minggu, 7 Juli 2024 pukul 04.30
23.
Neoadjuvant Immunotherapy for Patients with Non- Small Cell Lung Cancer-Is a New Era Coming? (AEGEAN study)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 04.30
-
Minggu, 7 Juli 2024 pukul 05.00
24.
Real-World Evidence of Immunotherapy for Lung Cancer (PACIFIC-R & CASPIAN case)
Oleh:
Fasilitator
Classical
Fairmont Hotel Jakarta
Minggu, 7 Juli 2024 pukul 05.00
-
Minggu, 7 Juli 2024 pukul 05.30
Yang Anda dapatkan di seminar ini :
19 JPL5 Satuan Kredit Profesi (SKP)
0 Menit total video Pembelajaran
19 Bahan bacaan
19 Konten dapat diunduh
Sertifikat kelulusanUlasan Seminar dari Peserta
4.9
4.9/5 (105 Ulasan)
90.48%
8.57%
0.95%
0%
0%
117
Peserta sudah mengikuti Seminar ini